Skip to main navigation Skip to search Skip to main content

Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry

  • Fei Chen
  • , Ravi K. Madduri
  • , Alex A. Rodriguez
  • , Burcu F. Darst
  • , Alisha Chou
  • , Xin Sheng
  • , Anqi Wang
  • , Jiayi Shen
  • , Edward J. Saunders
  • , Suhn K. Rhie
  • , Jeannette T. Bensen
  • , Sue A. Ingles
  • , Rick A. Kittles
  • , Sara S. Strom
  • , Benjamin A. Rybicki
  • , Barbara Nemesure
  • , William B. Isaacs
  • , Janet L. Stanford
  • , Wei Zheng
  • , Maureen Sanderson
  • Esther M. John, Jong Y. Park, Jianfeng Xu, Ying Wang, Sonja I. Berndt, Chad D. Huff, Edward D. Yeboah, Yao Tettey, Joseph Lachance, Wei Tang, Christopher T. Rentsch, Kelly Cho, Benjamin H. Mcmahon, Richard B. Biritwum, Andrew A. Adjei, Evelyn Tay, Ann Truelove, Shelley Niwa, Thomas A. Sellers, Kosj Yamoah, Adam B. Murphy, Dana C. Crawford, Alpa V. Patel, William S. Bush, Melinda C. Aldrich, Olivier Cussenot, Gyorgy Petrovics, Jennifer Cullen, Christine M. Neslund-Dudas, Mariana C. Stern, Zsofia Kote-Jarai, Koveela Govindasami, Michael B. Cook, Anand P. Chokkalingam, Ann W. Hsing, Phyllis J. Goodman, Thomas J. Hoffmann, Bettina F. Drake, Jennifer J. Hu, Jacob M. Keaton, Jacklyn N. Hellwege, Peter E. Clark, Mohamed Jalloh, Serigne M. Gueye, Lamine Niang, Olufemi Ogunbiyi, Michael O. Idowu, Olufemi Popoola, Akindele O. Adebiyi, Oseremen I. Aisuodionoe-Shadrach, Hafees O. Ajibola, Mustapha A. Jamda, Olabode P. Oluwole, Maxwell Nwegbu, Ben Adusei, Sunny Mante, Afua Darkwa-Abrahams, James E. Mensah, Halimatou Diop, Stephen K. Van Den Eeden, Pascal Blanchet, Jay H. Fowke, Graham Casey, Anselm J. Hennis, Alexander Lubwama, Ian M. Thompson, Robin Leach, Douglas F. Easton, Michael H. Preuss, Ruth J. Loos, Susan M. Gundell, Peggy Wan, James L. Mohler, Elizabeth T. Fontham, Gary J. Smith, Jack A. Taylor, Shiv Srivastava, Rosaline A. Eeles, John D. Carpten, Adam S. Kibel, Luc Multigner, Marie Élise Parent, Florence Menegaux, Geraldine Cancel-Tassin, Eric A. Klein, Caroline Andrews, Timothy R. Rebbeck, Laurent Brureau, Stefan Ambs, Todd L. Edwards, Stephen Watya, Stephen J. Chanock, John S. Witte, William J. Blot, J. Michael Gaziano, Amy C. Justice, David V. Conti, Christopher A. Haiman
  • University of Southern California
  • Argonne National Laboratory
  • Fred Hutchinson Cancer Research Center
  • The Institute of Cancer Research
  • University of North Carolina
  • University of North Carolina at Chapel Hill
  • City of Hope National Med Center
  • The University of Texas MD Anderson Cancer Center
  • Henry Ford Hospital
  • Stony Brook University
  • Johns Hopkins University
  • Vanderbilt University
  • Meharry Medical College
  • Stanford University School of Medicine
  • Moffitt Cancer Center
  • NorthShore University HealthSystem
  • American Cancer Society
  • National Institutes of Health
  • University of Ghana
  • Korle Bu Teaching Hospital
  • Georgia Institute of Technology
  • Yale University
  • VA Connecticut Healthcare System
  • London School of Hygiene & Tropical Medicine
  • Harvard Medical School
  • VA Medical Center
  • NM 87545
  • Westat
  • Northwestern University
  • Case Western Reserve University
  • Sorbonne Université
  • Tenon Hospital
  • Uniformed Services University of the Health Sciences
  • University of California, Berkeley
  • University of California at San Francisco
  • Washington University St. Louis
  • Sylvester Comprehensive Cancer Center
  • National Human Genome Research Institute (NHGRI)
  • Atrium Health/Levine Cancer Institute
  • Hôpital Général Idrissa Pouye
  • College of Medicine, University of Ibadan
  • University of Abuja
  • 37 Military Hospital
  • Hôpital Aristide Le Dantec
  • Kaiser Permanente Division of Research
  • University of California San Francisco
  • Paris Cité University and University of the Antilles
  • University of Tennessee Health Science Center
  • University of Virginia School of Medicine
  • Uro Care
  • CHRISTUS Santa Rosa Medical Center Hospital
  • University of Texas Health Science Center at San Antonio
  • University of Cambridge
  • Icahn School of Medicine at Mount Sinai
  • Roswell Park Cancer Institute
  • Louisiana State University Health Sciences Center
  • National Institute of Environmental Health Sciences (NIEHS)
  • Georgetown University
  • Royal Marsden NHS Foundation Trust
  • University Rennes
  • Centre Armand-Frappier Santé Biotechnologie
  • Faculté de Médecine
  • Université Paris-Sud
  • Cleveland Clinic Foundation
  • Dana-Farber Cancer Institute
  • Stanford University
  • Stanford Cancer Institute
  • International Epidemiology Institute
  • VA Boston Healthcare System

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)

Abstract

Background: Genetic factors play an important role in prostate cancer (PCa) susceptibility. Objective: To discover common genetic variants contributing to the risk of PCa in men of African ancestry. Design, setting, and participants: We conducted a meta-analysis of ten genome-wide association studies consisting of 19 378 cases and 61 620 controls of African ancestry. Outcome measurements and statistical analysis: Common genotyped and imputed variants were tested for their association with PCa risk. Novel susceptibility loci were identified and incorporated into a multiancestry polygenic risk score (PRS). The PRS was evaluated for associations with PCa risk and disease aggressiveness. Results and limitations: Nine novel susceptibility loci for PCa were identified, of which seven were only found or substantially more common in men of African ancestry, including an African-specific stop-gain variant in the prostate-specific gene anoctamin 7 (ANO7). A multiancestry PRS of 278 risk variants conferred strong associations with PCa risk in African ancestry studies (odds ratios [ORs] >3 and >5 for men in the top PRS decile and percentile, respectively). More importantly, compared with men in the 40–60% PRS category, men in the top PRS decile had a significantly higher risk of aggressive PCa (OR = 1.23, 95% confidence interval = 1.10–1.38, p = 4.4 × 10–4). Conclusions: This study demonstrates the importance of large-scale genetic studies in men of African ancestry for a better understanding of PCa susceptibility in this high-risk population and suggests a potential clinical utility of PRS in differentiating between the risks of developing aggressive and nonaggressive disease in men of African ancestry. Patient summary: In this large genetic study in men of African ancestry, we discovered nine novel prostate cancer (PCa) risk variants. We also showed that a multiancestry polygenic risk score was effective in stratifying PCa risk, and was able to differentiate risk of aggressive and nonaggressive disease.

Original languageEnglish
Pages (from-to)13-21
Number of pages9
JournalEuropean Urology
Volume84
Issue number1
DOIs
Publication statusPublished - Jul 2023
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • African ancestry
  • Aggressive prostate cancer
  • Polygenic risk score
  • Prostate cancer
  • Susceptibility loci

Fingerprint

Dive into the research topics of 'Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry'. Together they form a unique fingerprint.

Cite this